secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004750
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace reports Q4 2022 preliminary revenue $12.8M (+16% YoY); appoints Dr. Uri Geiger to board
--------------------------------------------------------------------------------

- Q4 2022 total revenue expected ~$12.8M, up 16% from $11.0M in Q4 2021; initial implant revenue $9.8M (+15%).
- Full-year 2022 revenue expected ~$45.5M, flat vs $45.2M in 2021; initial implant revenue $35.7M (+6%).
- Dr. Uri Geiger, founder of Accelmed Partners, appointed to Board effective Jan 5, 2023; granted option for 120,521 shares at $1.535.
- Replacement implant revenue declined 44% in Q4 ($1.4M) and 29% for FY2022 ($8.2M); DIXI Medical contributed $1.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/d407794d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer